Program
Naproxen
Also written as “PN400”, “naproxen” and “Naproxen Sodium (Aleve, BAY117031)”.
Its studies are mostly in Pain · Osteoarthritis · Migraine Disorders · Osteoarthritis, Knee · Pain, Postoperative, led by 12 companies.
Drug pageNaproxen: every studyMany companies study it; this page follows only the 65 they lead. All 150 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayerits history only | 240 open or running | phase 4since Apr 15, 2010 | Jun 5, 2008 | none ahead |
| Pfizerits history only | 80 open or running | phase 4since Mar 28, 2008 | Aug 17, 2006 | none ahead |
| GlaxoSmithKlineits history only | 70 open or running | phase 4since Nov 17, 2008 | Oct 14, 2005 | none ahead |
| Aralez Pharmaceuticalsits history only | 60 open or running | phase 3since Aug 18, 2006 | Aug 18, 2006 | none ahead |
| Johnson & Johnsonits history only | 50 open or running | phase 4since Dec 2, 2005 | Dec 2, 2005 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 40 open or running | phase 1since Jan 8, 2010 | Jan 8, 2010 | none ahead |
| Merckits history only | 40 open or running | phase 4since Sep 7, 2005 | Sep 7, 2005 | none ahead |
| Ache Laboratorios Farmaceuticosits history only | 20 open or running | phase 3since Jul 7, 2011 | Jul 7, 2011 | none ahead |
| Perrigoits history only | 20 open or running | phase 1since Dec 5, 2008 | Dec 5, 2008 | none ahead |
| Amgenits history only | 10 open or running | phase 2since Oct 19, 2012 | Oct 19, 2012 | none ahead |
| Analgesic Solutionsits history only | 10 open or running | no phasesince Feb 21, 2012 | Feb 21, 2012 | none ahead |
| Kenvue Brandsits history only | 11 open or running | phase 3since Oct 15, 2026 | Oct 15, 2026 | Oct 29, 2027phase 3 · NCT07948811 |
Also a collaborator on its studies: Teva Pharmaceutical Industries and Pegus Research.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Aug 17, 2006.
- Jan 12, 2018Phase 4 study in Pain, PostoperativeBayer · NCT03404206 · 387 enrolled · United States
- Feb 9, 2018Phase 4 study in DysmenorrheaBayer · NCT03448536 · 201 enrolled · United States
- Jun 18, 2018Phase 2 study in Osteoarthritis, KneeBayer · NCT03570554 · 41 enrolled · United States
- Oct 4, 2018Phase 1 study in HealthyJohnson & Johnson · NCT03697889 · 28 enrolled · Russian Federation
- Mar 1, 2019Phase 2 study in PainJohnson & Johnson · NCT03879408 · 290 enrolled · United States
- Oct 8, 2019Phase 2 study in Pain, PostoperativeBayer · NCT04132336 · 193 enrolled · United States
- Mar 5, 2020Phase 4 study in PainBayer · NCT04307940 · 221 enrolled · United States
- Jun 23, 2020Phase 2 study in PainJohnson & Johnson · NCT04447040 · 304 enrolled · United States
- Jul 12, 2021Phase 2 study in Soft Tissue InjuriesBayer · NCT05026320 · 76 enrolled · Germany
- Jul 28, 2022Phase 3 study in ToothacheBayer · NCT05485805 · 541 enrolled · United States
- Apr 25, 2023Phase 1 study in Orthodontic PainJohnson & Johnson · NCT05844995 · 24 enrolled · United States
- May 10, 2024Phase 1 study in PainBayer · NCT06415019 · 236 enrolled · United States
- Jul 11, 2024Phase 1 study in PainBayer · NCT06511973 · 42 enrolled · United States
- Oct 15, 2026Kenvue Brands’ first study: phase 3 study in FeverNew to Kenvue BrandsKenvue Brands · NCT07948811 · 292 planned · United States
Ahead
- Oct 29, 2027Primary completion: phase 3 study in FeverKenvue Brands · NCT07948811
TargetBeta
“Cyclooxygenase inhibitor; Cyclooxygenase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Acetaminophenrule | Johnson & Johnson | phase 4 | 137 |
| Ibuprofenrule | Pfizer | phase 4 | 113 |
| Aspirinrule | Bayer | phase 4 | 84 |
| dexketoprofenrule | Menarini Group | phase 4 | 8 |
| Sulfasalazinerule | Bristol-Myers Squibb | phase 4 | 7 |
| dexibuprofenrule | aponia-laboratories-inc | phase 4 | 6 |
| Benzydaminerule | Angelini Pharma | phase 4 | 4 |
| Dipyronerule | Hypera Pharma | phase 4 | 4 |
| Piroxicamrule | Taisho Pharmaceutical | phase 4 | 4 |
| Flurbiprofenrule | GlaxoSmithKline | phase 3 | 12 |
Studies
The newest 60 of 65 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07948811Fever · United States | 3 | Recruiting | Kenvue Brands | Oct 29, 2027 | 292 |
| NCT06511973Pain · United States | 1 | Completed | Bayer | Aug 20, 2024 | 42 |
| NCT06415019Pain · United States | 1 | Completed | Bayer | Aug 1, 2024 | 236 |
| NCT05844995Orthodontic Pain · United States | 1 | Completed | Johnson & Johnson | Feb 12, 2024 | 24 |
| NCT05485805Toothache · United States | 3 | Completed | Bayer | Jan 25, 2024 | 541 |
| NCT05026320Soft Tissue Injuries · Germany | 2 | Completed | Bayer | Dec 20, 2021 | 76 |
| NCT04447040Pain · United States | 2 | Completed | Johnson & Johnson | Apr 9, 2021 | 304 |
| NCT04307940Pain · United States | 4 | Completed | Bayer | Oct 2, 2020 | 221 |
| NCT04132336Pain, Postoperative · United States | 2 | Completed | Bayer | Mar 2, 2020 | 193 |
| NCT03879408Pain · United States | 2 | Completed | Johnson & Johnson | Nov 7, 2019 | 290 |
| NCT03697889Healthy · Russian Federation | 1 | Completed | Johnson & Johnson | Dec 17, 2018 | 28 |
| NCT03570554Osteoarthritis, Knee · United States | 2 | Completed | Bayer | Jun 14, 2019 | 41 |
| NCT03448536Dysmenorrhea · United States | 4 | Completed | Bayer | Sep 5, 2018 | 201 |
| NCT03404206Pain, Postoperative · United States | 4 | Completed | Bayer | Jul 6, 2018 | 387 |
| NCT02549469Pain | 1 | Completed | Bayer | May 2007 | 32 |
| NCT02229461Hematology · United States | 1 | Completed | Bayer | May 2015 | 117 |
| NCT01726920Migraine Disorders | 3 | Withdrawn | Ache Laboratorios Farmaceuticos | Dec 2014 | 0 |
| NCT01712009Breast Neoplasms · United States | 2 | Completed | Amgen | Mar 18, 2015 | 600 |
| NCT01557816Osteoarthritis, Knee · United States | – | UNKNOWN | Analgesic Solutions | Jun 2012 | 70 |
| NCT01495858Pain, Postoperative · United States | 3 | Completed | Bayer | Feb 2012 | 267 |
| NCT01427803Pain · United States | 3 | Completed | Bayer | Dec 2011 | 778 |
| NCT01390324Migraine Disorders | 3 | Withdrawn | Ache Laboratorios Farmaceuticos | Mar 2012 | 0 |
| NCT01389284Pain, Postoperative · United States | 3 | Completed | Bayer | Sep 2011 | 300 |
| NCT01383486Pain · United States | 3 | Completed | Bayer | Aug 2011 | 253 |
| NCT01365052Pain · United States | 3 | Completed | Bayer | Jul 2011 | 326 |
| NCT01280591Pain, Postoperative · United States | 3 | Completed | Bayer | Jan 2011 | 712 |
| NCT01231490Osteoarthritis · United Kingdom | 2 | Completed | GlaxoSmithKline | Jan 2009 | 53 |
| NCT01131767Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Aug 2004 | 26 |
| NCT01131728Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | Aug 2004 | 26 |
| NCT01118273Sleep · United States | 4 | Completed | Bayer | Feb 2008 | 162 |
| NCT01102660Osteoarthritis · United States | 2 | Completed | Pfizer | Feb 2011 | 172 |
| NCT01052792Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | May 2006 | 26 |
| NCT01052129Healthy · India | 1 | Completed | Dr. Reddy's Laboratories | May 2006 | 26 |
| NCT00969449Pharmacokinetics · United States | 1 | Completed | Bayer | May 2009 | 28 |
| NCT00844805Spondylitis, Ankylosing | 3 | Completed | Merck | Apr 2011 | 158 |
| NCT00843024Migraine Disorders · United States | 3 | Completed | GlaxoSmithKline | May 2010 | 589 |
| NCT00830050Osteoarthritis · United Kingdom | Early 1 | Completed | Pfizer | Dec 2010 | 24 |
| NCT00818415Pain · United States | 1 | Completed | Bayer | Nov 2008 | 32 |
| NCT00804401Bioequivalency | 1 | Completed | Perrigo | Jul 2004 | 34 |
| NCT00803764Bioequivalency | 1 | Completed | Perrigo | Jul 2004 | 34 |
| NCT00792636Migraine Disorders · United States | 4 | Completed | GlaxoSmithKline | Nov 2009 | 407 |
| NCT00772967Osteoarthritis | 1 | Completed | Merck | Nov 2008 | 22 |
| NCT00751556Healthy · United States | 1 | Completed | Bayer | Mar 2008 | 32 |
| NCT00751400Pain · United States | 3 | Completed | Bayer | Nov 2008 | 497 |
| NCT00743587Osteoarthritis Thumbs · Belgium | 1 | Completed | Pfizer | Mar 2009 | 36 |
| NCT00720057Toothache · United States | 3 | Completed | Bayer | Aug 2008 | 312 |
| NCT00692016Bioavailability · United States | 1 | Completed | Bayer | Feb 2008 | 32 |
| NCT00692055Arthritis · United States | 1 | Completed | Aralez Pharmaceuticals | Jul 2008 | 30 |
| NCT00676442Arthritis · United States | 1 | Completed | Aralez Pharmaceuticals | Jun 2008 | 24 |
| NCT00665743Arthritis · United States | 1 | Completed | Aralez Pharmaceuticals | Jun 2008 | 30 |
| NCT00652808Osteoarthritis · Korea, Republic of | 3 | Completed | Pfizer | 265 | |
| NCT00650455Arthritis, Rheumatoid · United States, Canada | 4 | Completed | Pfizer | Jan 2005 | 489 |
| NCT00648258Osteoarthritis · Taiwan | 3 | Completed | Pfizer | 130 | |
| NCT00601458Acute Pain | 1 | Completed | Merck | Jan 2008 | 100 |
| NCT00599404Healthy | 1 | Completed | Aralez Pharmaceuticals | Feb 2008 | 18 |
| NCT00442221Migraine Disorders · United States | 3 | Completed | Aralez Pharmaceuticals | 500 | |
| NCT00392080Osteoarthritis · United States | 1 | Completed | Pfizer | 340 | |
| NCT00387881Migraine without Aura · United States | 3 | Completed | GlaxoSmithKline | Feb 2008 | 679 |
| NCT00367211Osteoarthritis · United States | 3 | Completed | Aralez Pharmaceuticals | Sep 2007 | 400 |
| NCT00366262Healthy · United States | 1 | Completed | Pfizer |
How it is read
Names in the registry
- “Naproxen”, 17 entries
- “PN400”, 8 entries
- “naproxen”, 5 entries
- “Naproxen Sodium (Aleve, BAY117031)”, 4 entries
- “Naproxen Sodium ER (BAYH6689)”, 4 entries
Conditions, from the studies’ own filings
- Pain, 12 studies
- Osteoarthritis, 9 studies
- Migraine Disorders, 8 studies
- Osteoarthritis, Knee, 5 studies
- Pain, Postoperative, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.